Schizophrenia Research: Recent Advances

Tomiki Sumiyoshi (Editor)
University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan

Series: Mental Illnesses and Treatments
BISAC: PSY018000

Clear

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Schizophrenia is a relatively common disease whose lifetime prevalence in the general population is reported to be about 1%. From the perspective of public health, the illness has been associated with serious consequences. Besides psychotic symptoms, schizophrenia is characterized by disturbances of cognitive function, which is considered to largely determine the outcome of patients. The neural and genetic substrates underlying its pathophysiology have not been fully demarcated, posing a challenge for the development of breakthrough therapeutics. This book provides key information about the latest endeavor to solve these difficulties characterizing this enigmatic disease. (Imprint: Nova)

Preface

Chapter 1 - A model-based approach to schizophrenia research
(Shoji Tanaka, Department of Information and Communication Sciences, Sophia University, Tokyo, Japan)

Chapter 2 - How the degree of the linearity of the Brief Psychiatric Rating Scale be measured and improved: A retrospective analysis
(Jitsuki Sawamura, Shigeru Morishita, and Jun Ishigooka, Department of Psychiatry, Tokyo Women’s Medical University, Tokyo, Japan, and Depression Prevention Medical Center, Kyoto Jujo Rehabilitation Hospital, Kyoto, Japan)
Free Download Available

Chapter 3 - Quality of life and personal and social functioning: New targets in schizophrenia treatment
(Anna Galuppi, Maria Cristina Turola, and Paola Mazzoni, Section of Child Neurology and Psychiatry, Children’s Hospital A. Meyer–University of Florence, Italy, and Mental Health Department, Local Health Agency, Ferrara, Italy)

Chapter 4 - Natural-mortality in schizophrenia: An updated meta-analysis
(Carmen Bouza, Teresa López-Cuadrado, Zuleika Saz-Parkinson, Raimundo Alcázar Alcázar, and José María Amate Blanco, Health Technology Assessment Agency. Instituto de Salud Carlos III. Ministry of Science and Innovation. Madrid, Spain, and others)

Chapter 5 - Psychiatric nurses’ beliefs about the treatability of schizophrenia in Japan
(Setsuko Hanzawa, Kayomi Yatabe, Goro Tanaka, and Yoshibumi Nakane, School of Nursing, Jichi Medical University, Japan, and others)

Chapter 6 - Current neurobiological research in early onset schizophrenia
(Gianluca Serafini, Maurizio Pompili, Marco Innamorati, Gloria Giordano, Roberto Tatarelli, and Paolo Girardi, Department of Neurosciences, Mental Health and Sensory Functions; Suicide Prevention Center, Sant’Andrea Hospital, “Sapienza” University of Rome, Italy, and McLean Hospital, Harvard Medical School, USA)

Chapter 7 - White matter abnormalities in schizophrenia patients and genetic high-risk subjects
(Xiaobo Li, and Lynn E. Delisi, Gruss Magnetic Resonance Research Center, Department of Radiology, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, and VA Boston Healthcare System, Harvard Medical School, Brockton, MA)

Chapter 8 - Depth Perception Deficits in Schizophrenia
(Jamie K. Opper, Patrick Monnier, Deana Davalos ,Department of Psychology, Colorado State University. Fort Collins, CO 80523 USA)

Chapter 9 - Emotional startle modulation in male patients with recent-onset schizophrenia
(Roelie J. Hempel, Hugo G. van Steenis, Nico J.M. van Beveren, Christian H. Röder, and Joke H. M. Tulen, Department of Psychiatry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, and Department of Psychology, University of Southampton, Southampton, United Kingdom)

Chapter 10 - The prospective epigenetic keys for the inflammatory puzzle of schizophrenia
(Aren Khoyetsyan, Anna Boyajyan, Institute of Molecular Biology, Armenian National Academy of Sciences, Yerevan, Republic of Armenia)

Chapter 11 - Molecular and genetic indicators of aberrant immunity and apoptosis in schizophrenia
(Anna Boyajyan, Roksana Zakharyan, Aren Khoyetsyan, Institute of Molecular Biology, Armenian National Academy of Sciences, Yerevan, Republic of Armenia)

Chapter 12 - Antipsychotics, social cognition and outcome
(Alessandro De Risio, NSH Health Trust No. 10 “Veneto Orientale”, Unit of Psychiatry of Portogruaro, Venice, Italy)
Free Download Available

Chapter 13 - Cognitive deficits in pharmacological rodent models of schizophrenia: Evaluation of spatial cognition
(Tereza Nekovarova, Ales Stuchlik, Karel Vales, Lukas Rambousek, and Tomiki Sumiyoshi, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic, and others)

Chapter 14 - Management of cognitive impairment in schizophrenia: therapeutic role of 5-HT receptors
(Yukihiro Ohno, Ayaka Tatara, Saki Shimizu, and Masashi Sasa, Laboratory of Pharmacology, Osaka University of Pharmaceutical Sciences, Japan, and Nagisa Clinic, Osaka, Japan)

Chapter 15 - Gene polymorphism at serotonin 5-HT1A receptors: Moving towards personalized medicine for psychosis and mood deficits?
(Adrian Newman-Tancredi, and Paul R. Albert, NeuroAct Communication, Castres, France, and University of Ottawa, Ottawa, Canada)

Chapter 16 - Repetitive transcranial magnetic stimulation: A new option to manage negative symptoms of schizophrenia
(Radovan Prikryl, Libor Ustohal, and Hana Prikrylova Kucerova, Central European Institute of Technology, Masaryk University Brno, Czech Republic, and Department of Psychiatry Faculty of Medicine Masaryk University and University Hospital Brno, Czech Republic)

Index pp.381-398

You have not viewed any product yet.